Papers in BMJ Oncology
Page 2 · newest first
- KRAS-targeted therapies in cancer: novel approaches and overcoming resistanceBMJ Oncology · 2025
- Alkylating-induced hypermutation in pancreatic neuroendocrine tumoursBMJ Oncology · 2025
- KRAS-targeted therapies in cancer: novel approaches and overcoming resistanceBMJ Oncology · 2025
- Digital twins in oncology: where we are and where we hope to goBMJ Oncology · 2025
- Alkylating-induced hypermutation in pancreatic neuroendocrine tumoursBMJ Oncology · 2025
- Incidence of fractures in patients with solid cancers treated with immune checkpoint inhibitors: a systematic review and meta-analysis of randomised controlled trialsBMJ Oncology · 2025
- Impact of loneliness on cancer mortality: a systematic review and meta-analysisBMJ Oncology · 2025
- Clinical prediction models using machine learning in oncology: challenges and recommendationsBMJ Oncology · 2025
- WHO is embedding inequality into cancer diagnosticsBMJ Oncology · 2025
- Understanding characteristics of contemporary cancer survival for modelling the cost-effectiveness of new interventionsBMJ Oncology · 2025
- Sensory neuropeptide CGRP and its co-receptor RAMP1 drive tumour cell growth in gastrointestinal cancersBMJ Oncology · 2025
- Qualitative study of oncologists’ perceptions on the US Food and Drug Administration approval status and clinical practice guidelines and their impact on local practice patterns in IndiaBMJ Oncology · 2025
- Analysis of control arms in oncology randomised trials in Brazil: a cross-sectional studyBMJ Oncology · 2025
- Tumour-infiltrating lymphocyte therapy landscape: prospects and challengesBMJ Oncology · 2025
- Concordance with CONSORT-AI guidelines in reporting of randomised controlled trials investigating artificial intelligence in oncology: a systematic reviewBMJ Oncology · 2025
- Five years after CONSORT-AI, not much has changed: a call to action for artificial intelligence research in oncologyBMJ Oncology · 2025
- Inferior control arms in oncology trials in LMICs: contextualised or compromised?BMJ Oncology · 2025
- Elucidating the mechanisms of lifestyle interventions in mitigating radiotherapy adverse effects: a scoping reviewBMJ Oncology · 2025
- Microbial imprints on colorectal cancer: the epigenetic silencing of PHLPP1 as a prognostic nexusBMJ Oncology · 2025
- Chemotherapy and radiotherapy use in patients with lung cancer in Australia, Canada, the UK and Norway 2012–2017: an ICBP population-based studyBMJ Oncology · 2025
- Colorectal cancer patient outcome is influenced by tumour-adherent bacteria through epigenetic regulation of cardinal genes including PHLPP1BMJ Oncology · 2025
- Real-world experience on efficacy and safety of different adjuvant chemotherapy regimens in locoregionally advanced nasopharyngeal carcinomaBMJ Oncology · 2025
- Extending the functional lifespan of natural killer (NK) cells: towards durable cytotoxicity in NK-cell based immunotherapyBMJ Oncology · 2025
- Cancer incidence and diagnostic characteristics in people with intellectual disabilities in the Netherlands: a national registry-based cohort studyBMJ Oncology · 2025
- Identification of protein biomarker candidates associated with organ-specific immune-related toxicity and response to management by plasma proteomicsBMJ Oncology · 2025
- Smoking habit and long-term colorectal cancer incidence by exome-wide mutational and neoantigen loads: evidence based on the prospective cohort incident-tumour biobank methodBMJ Oncology · 2025
- Reduced duration adjuvant trastuzumab in the treatment of patients with HER2-positive breast cancer: a meta-analysis of randomised controlled non-inferiority trials including IPD dataBMJ Oncology · 2025
- Osteoclast-expanded supercharged NK cells perform superior antitumour effector functionsBMJ Oncology · 2025
- Patient-reported outcomes (PROs) in clinical trials and in clinical practice: report from the XXI national conference of the Italian Association of Medical Oncology (AIOM)BMJ Oncology · 2025
- Mismatch in testing: a retrospective analysis of mismatch repair testing in endometrial cancer and Lynch syndrome diagnosis in multiple specialist centres in the UK and Ireland (March 2022–March 2023)BMJ Oncology · 2025
- Symptoms, side effects, quality of life and financial toxicity matter to patients with cancer, we need to do a better job of capturing and reporting these concepts in trials and clinical careBMJ Oncology · 2025
- Large language models in oncology: a reviewBMJ Oncology · 2025
- Combined immune checkpoint inhibitors and ablative radiotherapy in metastatic cancers: a meta-analysis of prospective clinical trialsBMJ Oncology · 2025
- Disease-free survival as a surrogate for overall survival in early-stage pancreatic cancer trials: a correlation meta-analysisBMJ Oncology · 2025
- Specificity of Food and Drug Administration postmarketing requirements and associations with timely submissions and regulatory decisions for oncology accelerated approvals, 2011–2023: a cross-sectional analysisBMJ Oncology · 2025
- Mental healthcare utilisation among individuals with colorectal cancer: population-based cohort studiesBMJ Oncology · 2025
- Geographic, socioeconomic and demographic inequalities in the incidence of metastatic prostate cancer at time of diagnosis in England: a population-based evaluationBMJ Oncology · 2025
- Souped-up natural killer (NK) cells for treating tough cancersBMJ Oncology · 2025
- A systematic review comparing surveillance recommendations for the detection of recurrence following surgery across 16 common cancer typesBMJ Oncology · 2025
- Associations of DNA methylation in breast tumour subtypes with parity and breastfeeding in a cohort of 1459 Black women: implications for public healthBMJ Oncology · 2025
- Air pollution and its impact on cancer incidence, cancer care and cancer outcomesBMJ Oncology · 2025
- Impact of resection margin width on local recurrence following breast-conserving surgery and whole breast radiotherapy for pure ductal carcinoma in situ: a systematic review and meta-analysisBMJ Oncology · 2025
- TERT promoter mutations or protein overexpression define an aggressive subset with favourable immunotherapeutic response in advanced urothelial carcinomaBMJ Oncology · 2025
- Immunotherapy response in immunosuppressed patients with Merkel cell carcinoma: analysis of 183 patientsBMJ Oncology · 2025
- Whole-body integral dose and post-radiotherapy lymphocytopaenia in solid tumoursBMJ Oncology · 2025
- Genetics, primary care records and lifestyle factors for short-term dynamic risk prediction of colorectal cancer: prospective study of asymptomatic and symptomatic UK Biobank participantsBMJ Oncology · 2025
- Predicting short-term risk of colorectal cancer using primary care records, genetics and lifestyle factorsBMJ Oncology · 2025
- Advancing cancer care through digital access in the USA: a state-of-the-art review of patient portals in oncologyBMJ Oncology · 2025
- Thirty years from FDA approval of pegylated liposomal doxorubicin (Doxil/Caelyx): an updated analysis and future perspectiveBMJ Oncology · 2025
- UK-based clinical testing programme for somatic and germline BRCA1/2, ATM and CDK12 mutations in prostate cancer: first resultsBMJ Oncology · 2025